echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Amgen's new psoriasis drug, Apomilast tablets, approved for marketing

    Amgen's new psoriasis drug, Apomilast tablets, approved for marketing

    • Last Update: 2021-08-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On August 16, the official website of NMPA showed that Amgen’s new imported drug Apomilast tablets was approved to be marketed for psoriasis


    Apomilast tablets (formerly known as Apomilast tablets) is a small molecule inhibitor of phosphodiesterase 4 (PDE4)


    Chemical structure of Apomilast tablets, picture source: drug insert

    Apomilast tablets were developed by Celgene and launched in the United States in 2014 (trade name: Otezla).


    In August 2019, Amgen announced that it had obtained Apomilast at a price of up to 13.


    Apomilast is the first oral drug approved for psoriasis in the past 20 years and the first oral drug approved for PsA in the past 15 years


    Such a heavy variety naturally attracts the active layout of domestic enterprises


    According to the Insight database, in addition to Amgen, there are six domestic companies whose applications for the listing of Apmaster tablets are under review


    From the Insight database (http://db.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.